Condition
Severe Acute Respiratory Syndrome (SARS)
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06002841Phase 1UnknownPrimary
Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure
NCT04432272Phase 2Terminated
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
NCT04365985Phase 2Terminated
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Showing all 3 trials